Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis

References

• Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun 1985;129:701–6
   PubMed Web of Science ®Google Scholar
• Giorgetti S, Stoppini M, Tennent GA, Relini A, Marchese L, Raimondi S, Monti M, et al. Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Sci 2007;16:343–9
   PubMed Web of Science ®Google Scholar
• Giorgetti S, Raimondi S, Cassinelli S, Bucciantini M, Stefani M, Gregorini G, Albonico G, et al. beta2-microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. Nephrol Dial Transplant 2009;24:1176–81
   PubMed Web of Science ®Google Scholar
• Danesh F, Ho LT. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial 2001;14:80–5
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kazama JJ, Maruyama H, Nishi S, Narita I, Gejyo F. Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders. Clin Nephrol 2008;70:496–502
   PubMed Web of Science ®Google Scholar
• Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, Lavatelli F, et al. The workings of the amyloid diseases. Ann Med 2007;39:200–7
   PubMed Web of Science ®Google Scholar
• De Lorenzi E, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V. Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a “protein misfolding disease”. Curr Med Chem 2004;11:1065–84
   PubMed Web of Science ®Google Scholar
• Woods LA, Platt GW, Hellewell AL, Hewitt EW, Homans SW, Ashcroft AE, Radford SE. Ligand binding to distinct states diverts aggregateion of an amyloid-forming protein. Nat Chem Biol 2011;28:730–9
   Google Scholar
• Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, Corazza A, Fogolari F, et al. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem 2011;286:2121–31
   PubMed Web of Science ®Google Scholar
• Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995;92:2959–63
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000;300:1309–22
   PubMed Web of Science ®Google Scholar
• De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One 2008;3:e1888
   PubMed Web of Science ®Google Scholar
• Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 2006;20:234–9
   PubMed Web of Science ®Google Scholar
• Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001;487:404–7
   PubMed Web of Science ®Google Scholar
• Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, Doglia SM, et al. Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 2010;40:424–31
   PubMed Web of Science ®Google Scholar
• Aitken JF, Loomes KM, Konarkowska B, Cooper GJ. Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. Biochem J 2003;374:779–84
   PubMed Web of Science ®Google Scholar
• Aitken JF, Loomes KM, Scott DW, Reddy S, Phillips AR, Prijic G, Fernando C, et al. Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice. Diabetes 2010;59:161–71
   PubMed Web of Science ®Google Scholar
• Malmo C, Vilasi S, Iannuzzi C, Tacchi S, Cametti C, Irace G, Sirangelo I. Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state. FASEB J 2006;20:346–67
   PubMed Web of Science ®Google Scholar
• Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J Am Geriatr Soc 2004;52:381–7
   PubMed Web of Science ®Google Scholar
• Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19:34–6
   PubMed Web of Science ®Google Scholar
• Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003;791:337–43
   PubMed Web of Science ®Google Scholar
• Montagna G, Raimondi S, Moro G, Uggetti C, Relini A, Magrini U, Esposito G, et al. Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid 2009;16:115–21
   PubMed Web of Science ®Google Scholar
• Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 1983;16:245–52
   PubMed Web of Science ®Google Scholar
• Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355–66
   PubMed Web of Science ®Google Scholar
• Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007;25:133–5
   PubMed Web of Science ®Google Scholar
• Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol Res 2011;64:610–3
   PubMed Web of Science ®Google Scholar
• Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol 2008;18:771–9
   PubMed Web of Science ®Google Scholar
• Mourad G, Argilés A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996;7:798–804
   PubMed Web of Science ®Google Scholar
• Campistol JM. Dialysis-related amyloidosis after renal transplantation. Semin Dial 2001;14:99–102
   PubMed Web of Science ®Google Scholar
• Gejyo F, Amano I, Ando T, Ishida M, Obayashi S, Ogawa H, Ono T, et al. Society of β2-Microglobulin Adsorption Therapy. Survey of the effects of a column for adsorption of β2-microglobulin in patients with dialysis-related amyloidosis in Japan. Ther Apher Dial 2013;17:40–7
   PubMed Web of Science ®Google Scholar
• Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, et al. European Uremic Toxin Work Group (EUTox). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 2012;12:1297–303
   Google Scholar